SOURCE: Kureczka/Martin Associates
NEW YORK, NY--(Marketwired - Mar 10, 2014) - The 4th Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference will take place on March 27, 2014 at the New York Academy of Medicine in New York City. This unique, single-day conference event unites key opinion leaders in Immuno-oncology, Wall Street research analysts, venture capitalists, institutional investors, media, and company executives: CEO, CFO, CSO, CMO, Heads of Business Development to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of Immuno-oncology.
Keynote speakers and panels will feature discussions by noted scientific and clinical thought leaders, industry executives, and institutional investors on
- "Engineered T cells for cancer immunotherapy: Progress and Challenges"
- "Treatment of B cell malignancies with CD19-specific CAR-modified T cells"
- "Immunotherapy in Oncology: Understanding The Kinetics of Responses May be Key to Future Development"
- Autologous Immunotherapies
- Checkpoint Inhibitors
- "Combination Immunotherapy: Enhancing monoclonal antibody activity through checkpoint modulation"
- Targeted Peptide Approach to Vaccines in Breast and Ovarian Cancers
- Emerging Role of Combination Tumor Immunotherapies, and other topical presentations, including
- Lunchtime panel discussion "The High Cost of Innovation: Who Will Pay?" featuring viewpoints from technology developers, reimbursement experts, and the medical community.
Key opinion leaders who will present include:
David Berd, MD -- Former Director of Immunology, CTCA; CMO AVAX Technologies
Reiner Laus, MD -- Strategic Advisor; Former President & CEO, Bavarian Nordic Immunotherapeutics
Keith Knutson, Ph.D., is Director of the Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida
Holbrook Kohrt, MD, Ph.D. -- Assistant Professor Division of Oncology, Department of Medicine, Stanford University School of Medicine
Ravi A. Madan, MD -- Clinical Director, Genitourinary Malignancies Branch, National Cancer Institute
Rimas Orentas, Ph.D. -- Associate Scientist in the Pediatric Oncology, Branch of the National Cancer Institute's Center for Cancer Research at the National Institute of Health
Col. George E. Peoples, MD, FACS -- Brooke Army Medical Center
Cameron J. Turtle, MD, PhD -- Hematology Oncologist, Clinical Research Division at the Fred Hutchinson Cancer Research Center
"The conference provides an excellent opportunity to increase your knowledge of the advances and developments in Immuno-oncology," said Janet L. Dally, Founder and managing director of MaidStone Life Sciences, LLC. "The intimate venue will also allow attendees to build relationships with industry experts. The agenda for this event includes Immuno-oncology topical, presentations, panel discussions, case examples, question and answer sessions, a corporate presentation track and excellent networking opportunities."
MaidStone Life Sciences LLC is the host for the event, with support from Kureczka/Martin Associates. The meeting is also sponsored by BOOZ & Co, BioPharm Insight and Shenkel/Stegman Communications Design.
For more information about the event, please visit the event website at http://www.maidstonels.com/conference.html. For information regarding conference registration, sponsorship opportunities, and one of the limited company presentation slots available please contact Janet Dally at 609-466-0466 or firstname.lastname@example.org. Members of the media wishing to attend the event should contact Joan Kureczka at Joan@kureczka-martin.com or call 415-821-2413.
About MaidStone Life Sciences, LLC
MSLS is a strategic advisor and partner, providing a full range of services to help our clients increase visibility, unlock stakeholder value and access resources to grow their business. We are a boutique management, investor relations and strategy consulting firm focusing on both public and private companies in the life sciences industry. We have an extensive network of venture capitalists, institutional investors, high net worth individuals, and other sources of capital.